Catalyst Wire Dossier Catalyst Wire Dossier

131I-Sibrotuzumab

sibrotuzumab · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 131I-Sibrotuzumab, covering 2014-08-06 to 2014-08-06. Get the full timeline:

Most recent: Clinical Trial Update: Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer [Phase 1]

See pricing